Smith & Nephew Advanced Wound Management provides high quality products, medical education and services supporting initial wound bed preparation through to full wound closure, enabling better outcomes for patients and healthcare systems.
With a wide portfolio of wound care products targeting chronic and acute wounds, we take a pioneering approach to the design of our products and services and strive to secure wider access to our technologies for more customers.
Wound care solutions
Wound management can be a complex treatment area, with chronic wounds, acute wounds and surgical wounds each having their own characteristics; but wounds, much like the people affected by them, need to be treated on an individual basis.
At Smith & Nephew we strive to secure wide access to our advanced wound care solutions by making our product portfolio available, accessible and cost effective to the world’s constantly evolving healthcare systems.
With solutions for wound prevention, initial wound bed preparation, though to full wound closure, supported by a continual stream of pioneering product development, we’re working hard to support your management of those affected by wounds, enabling better outcomes for your patients, and your budgets.
Chronic wounds are generally associated with an aging population, with pressure sores, venous leg ulcers, and diabetic foot ulcers being typical examples. Healing chronic wounds can be a challenging task. These wounds often produce high amounts of exudate and are frequently exposed to the risk of infection.
The ALLEVYN◊ family of dressings is designed though a process of intensive research and cutting edge technology to help you provide your patients with the best path to wound closure.
ALLEVYN’s advanced foam dressing technology has been enhanced greatly in recent years with new versions being introduced to the range. These dressings provide efficient fluid management and an optimal moist wound environment that promotes faster healing of the wound1, reduced risk of maceration and protection from infection2.
Find out more about the ALLEVYN Range of dressings
Then, there’s DURAFIBER◊, a highly absorbent, non-woven gelling fibre filler dressing. Composed from a unique blend of cellulose based fibres, DURAFIBER provides a versatile solution for the management of medium to heavily exuding chronic and acute full thickness, partial thickness or shallow granulating wounds.
Infection management is a vital part of the wound healing process and we’re always conscious of every opportunity to reduce the incidence of infections when developing new products.
“Wound Infection continues to be a challenging problem world-wide, representing a considerable healthcare burden. Early recognition, along with prompt, appropriate and effective intervention, are more important than ever in reducing economic and health consequences, especially in the context of growing resistance to antitbioics.”
Professor Keith Harding
Wound Infection in clinical practise: shaping the future
A Consensus Document (2008)
The ACTICOAT◊ family are a unique range of antimicrobial barrier dressings for use over partial, full thickness and acute wounds, proven to improve outcomes for patients and budgets9,10
IODOSORB◊ and IODOFLEX◊ are cadexomer matrix dressings containing iodine. This range of cadexomer based products contains 0.9% iodine to effectively remove multiple barriers to healing and has been shown to reduce pain and odour associated with chronic wounds3.
Negative Pressure Wound Therapy
Negative Pressure Wound Therapy (NPWT) is one of the oldest forms of medicinal therapy used to heal the human body.
Over the past decade there has been a significant increase in the use of this therapy and today NPWT provides clinicians with an important option for the advanced management of a variety of chronic and acute wounds.
The PICO◊ System, our latest innovation, provides single use Negative Pressure Wound Therapy, while RENASYS◊ offers you flexibility through a choice of easy to use, intuitive devices and a range of foam and gauze dressing kits.
Bioactives represent the fastest growing category of chronic wound therapeutics. Our diversified biotherapeutics portfolio offers novel, cost-effective solutions for tissue repair and healing, addressing the full spectrum of hard-to-heal wounds.
Currently our leading product is Collagenase SANTYL◊ ointment, the only FDA-approved biologic enzymatic debriding agents for chronic dermal ulcers and severe burns. Other products including REGRANEX◊ Gel, a FDA-approved platelet-derived growth factor; and the OASIS® family of naturally-derived, extracellular matrix replacement products indicated for the management of both chronic and traumatic wounds.
A pioneering approach to product design & development
Our product development scientists combine intensive research with pioneering technology, creating products that support the needs of both patients and the healthcare professionals treating them.
ALLEVYN Life is exceeding expectations through a number of key innovations. These differentiating core design features contribute to better outcomes, such as improvements in patient wellbeing6,7 and clinician satisfaction.7
Since its introduction, ALLEVYN Life has been shown to contribute to patient wellbeing improvements7 and delivering economic benefits8
Ethnographic research has led to the development of the PICO range of NPWT solutions to include a new soft port, designed to remove the risk of pressure points4 which contribute to patient comfort in wear, and a new, multisite dressing design for improved ease of application, better conformability to improve fit and seal to awkward anatomical areas such as heels, and additional flexibility in the positioning of the dressing around curves and joints5.
View more information about the range of advanced wound management products from Smith & Nephew
1 Smith & Nephew Data on File 0711080, Absorption Properties of ALLEVYN Gentle Border, Tompkins L, November 2007
2 Smith & Nephew Data on File 1010016,Bacterial barrier testing (wet-wet) on samples of ALLEVYN Gentle, ALLEVYN Gentle Border dressings with a 7 day duration against S. Marcescens, Vaughan J., October 2010
3 Sundberg J and Meller R. A retrospective review of the use of cadexomer iodine in th treatment of chronic wounds. Wounds (1997), 9(3): 68-86
4 DL/14/065/R - Comparison of pressure transmission through port area of current PICO and Palermo designs. Casey C.
5 OR DOF 42 A Volunteer Trial to Assess Dressing Performance of PICO Multisite vs. Control. Palmer S, April 2014
6 Bali and Monterey Research Insights Summary Document. Smith & Nephew 2013.
7 Rossington A et al., Clinical performance and positive impact on patient wellbeing of ALLEVYN Life. Wounds UK 2013, Vol 9, No 4
8 Stephen-Haynes et al., An appraisal of the clinical performance and economic benefits of a silicone foam in a large UK primary care organisation. Journal of Community Nursing 2013.
9 ACTICOAT has been shown in a clinical trial to eliminate all signs and symptoms of wound infection within 2 weeks in 60% of cases Gago M, et al., Wounds 2008; 20(10): 273-278
10 Searle and Bielby (2010) Dressing strategies for the management of infected wounds in community wound care: impacts and implications. Poster at Wounds UK, Harrogate Nov 2010.